JN Nova Pharma Inc
Headquarters: Ontario
Summary
JN Nova Pharma is a Canadian biotechnology company developing a proprietary platform technology to address multiple high-value unmet medical needs, including acute respiratory distress syndrome (ARDS), Idiopathic Pulmonary Fibrosis (IPF), Acute Kidney Injury (AKI). Our platform technology collectively targets global market opportunities exceeding $40 billion. We are interested in identifying co-development partners and clinical centers in Korea to conduct the clinicals studies in 2027.
About
JN Nova Pharma is a private Canadian biotechnology company advancing innovative therapeutics for critical unmet medical needs. The company has received authorization from Health Canada to initiate Phase I clinical studies at McMaster University, marking a significant milestone in the clinical development of its lead therapeutic platform. JN Nova Pharma's Health Emergency Program is focused on addressing major medical challenges associated with radiation exposure, emerging viral threats, and severe pathogen-induced complications, including: • Acute Respiratory Distress Syndrome (ARDS) • Idiopathic Pulmonary Fibrosis (IPF) • Acute Kidney Injury (AKI) The company's proprietary therapeutic platform possesses important renal, cardiovascular, and pulmonary protective properties. JN Nova Pharma holds exclusive worldwide rights to this novel product class, which was discovered and is being developed in collaboration with leading Canadian academic institutions and contract research organizations (CROs).